Literature DB >> 26860486

Mapping of the OAB-SF Questionnaire onto EQ-5D in Spanish Patients with Overactive Bladder.

Miguel A Ruiz1, Laura L Gutiérrez1, Manuel Monroy1, Javier Rejas2.   

Abstract

BACKGROUND AND
OBJECTIVE: Mapping disease-specific measures onto generic preference-based indexes allows estimating utility values in specific conditions to determine gain of quality-adjusted-life-years when the status of condition varies. The aim of this study was to map a disease specific scale, the Overactive Bladder Questionnaire 5-dimensional health classification system (OAB-5D) derived from the Overactive Bladder questionnaire-Short Form (OABq-SF), onto a preference-based scale, the EuroQol-5D (EQ-5D), in a sample of patients with overactive bladder (OAB) in a Spanish population.
METHOD: A survey addressed to value the health states was conducted among 246 patients at 18 clinics of urology from Spain. A total of 43 out of 243 possible health states have been valued, using VAS (Visual Analog Scale) and TTO (time trade-off) techniques. In addition, ordinary least squares (OLS), generalized linear models (GLM) and Tobit models were estimated. Resulting models were compared and the best one was selected in terms of goodness of fit measures, attribute sign, coefficient magnitude, and statistical significance of regression coefficients. Finally, the internal validity of the best model was calculated by bootstrap resampling.
RESULTS: The best model to map the OAB-5D onto EQ-5D could be estimated and the stability of parameter estimations was proved. The mentioned model estimated through OLS regression attained R (2) value of 0.892, with the aggregated data; with GLM (efficient maximum likelihood regression), Pearson χ (2) of 15.3 has been obtained; AIC (Akaike information criterion) = -550.9 and BIC (Bayesian information criterion) = -475.4. OLS model included the following OABq-SF items (and range of weights): A1 (0.102, 0.216); A3 (0.070, 0.171); B3 (0.071, 0.078); B1 (0.076, 0.136); B2 (-0.132, -0.028).
CONCLUSION: It is possible to map the OAB-5D scores onto EQ-5D in the Spanish population, allowing estimating EQ-5D utility scores from OAB specific health conditions.

Entities:  

Mesh:

Year:  2016        PMID: 26860486     DOI: 10.1007/s40261-016-0377-z

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  32 in total

1.  Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D.

Authors:  Matthijs M Versteegh; Annemieke Leunis; Jolanda J Luime; Mike Boggild; Carin A Uyl-de Groot; Elly A Stolk
Journal:  Med Decis Making       Date:  2011-11-22       Impact factor: 2.583

2.  Inference in regression models of heavily skewed alcohol use data: a comparison of ordinary least squares, generalized linear models, and bootstrap resampling.

Authors:  Dan J Neal; Jeffrey S Simons
Journal:  Psychol Addict Behav       Date:  2007-12

3.  Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences.

Authors:  Ralph Crott; Andrew Briggs
Journal:  Eur J Health Econ       Date:  2010-05-16

4.  Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients.

Authors:  Eun-ju Kim; Su-Kyoung Ko; Hye-Young Kang
Journal:  Qual Life Res       Date:  2011-10-20       Impact factor: 4.147

5.  A median model for predicting United States population-based EQ-5D health state preferences.

Authors:  James W Shaw; A Simon Pickard; Shengsheng Yu; Shijie Chen; Vincent G Iannacchione; Jeffrey A Johnson; Stephen Joel Coons
Journal:  Value Health       Date:  2009-12-04       Impact factor: 5.725

6.  Mapping visual analogue scale health state valuations onto standard gamble and time trade-off values.

Authors:  P Dolan; M Sutton
Journal:  Soc Sci Med       Date:  1997-05       Impact factor: 4.634

7.  Quality of life in patients with overactive bladder: validation and psychometric properties of the Spanish Overactive Bladder Questionnaire-short Form.

Authors:  Salvador Arlandis; Miguel A Ruiz; Carlos Errando; Felipe Villacampa; Daniel Arumí; Isabel Lizarraga; Javier Rejas
Journal:  Clin Drug Investig       Date:  2012-08-01       Impact factor: 2.859

8.  The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS.

Authors:  Karin S Coyne; Chris C Sexton; Zoe S Kopp; Caty Ebel-Bitoun; Ian Milsom; Chris Chapple
Journal:  BJU Int       Date:  2011-03-03       Impact factor: 5.588

9.  Prevalence and burden of overactive bladder in the United States.

Authors:  W F Stewart; J B Van Rooyen; G W Cundiff; P Abrams; A R Herzog; R Corey; T L Hunt; A J Wein
Journal:  World J Urol       Date:  2002-11-15       Impact factor: 4.226

10.  An exploratory study to test the impact on three "bolt-on" items to the EQ-5D.

Authors:  Yaling Yang; Donna Rowen; John Brazier; Aki Tsuchiya; Tracey Young; Louise Longworth
Journal:  Value Health       Date:  2014-11-18       Impact factor: 5.725

View more
  3 in total

1.  Cost-effectiveness analysis of fesoterodine flexible dose in newly diagnosed patients with overactive bladder in routine clinical practice in Spain.

Authors:  Carmen Peral; Francisco Sánchez-Ballester; José M García-Mediero; Jaime Ramos; Javier Rejas
Journal:  Clinicoecon Outcomes Res       Date:  2016-09-26

Review 2.  Review and critical appraisal of studies mapping from quality of life or clinical measures to EQ-5D: an online database and application of the MAPS statement.

Authors:  Helen Dakin; Lucy Abel; Richéal Burns; Yaling Yang
Journal:  Health Qual Life Outcomes       Date:  2018-02-12       Impact factor: 3.186

3.  Health-related quality of life in patients with esophageal cancer or precancerous lesions assessed by EQ-5D: A multicenter cross-sectional study.

Authors:  Youqing Wang; Jufang Shi; Lingbin Du; Huiyao Huang; Le Wang; Juan Zhu; Huizhang Li; Yana Bai; Xianzhen Liao; Ayan Mao; Guoxiang Liu; Jiansong Ren; Xiaojie Sun; Jiyong Gong; Qi Zhou; Ling Mai; Lin Zhu; Xiaojing Xing; Yuqin Liu; Ying Ren; Bingbing Song; Li Lan; Jinyi Zhou; Peian Lou; Xiaohua Sun; Xiao Qi; Shouling Wu; Wenqiang Wei; Kai Zhang; Min Dai; Wanqing Chen; Jie He
Journal:  Thorac Cancer       Date:  2020-03-04       Impact factor: 3.500

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.